恶性胸膜间皮瘤的当前管理趋势 - Suppr

Suppr

超能文献

Current trends in the management of malignant pleural mesothelioma.

作者信息

Tsiouris Athanasios, Gourgoulianis Konstandinos I, Walesby Robin K

出版信息

Expert Rev Anticancer Ther. 2006 Jun;6(6):831-3. doi: 10.1586/14737140.6.6.831.

DOI:10.1586/14737140.6.6.831

PMID:16761925

Abstract

摘要

相似文献

Current trends in the management of malignant pleural mesothelioma.

Expert Rev Anticancer Ther. 2006 Jun;6(6):831-3. doi: 10.1586/14737140.6.6.831.

[Therapy of malignant pleural mesothelioma].

Med Klin (Munich). 1991 May 15;86(5):259-62.

Integration of multimodality approaches in the management of malignant pleural mesothelioma.

Clin Lung Cancer. 2004 Mar;5(5):290-8. doi: 10.3816/CLC.2004.n.008.

Trimodality therapy for malignant pleural mesothelioma.

Ann Thorac Surg. 2009 Sep;88(3):870-5; discussion 876. doi: 10.1016/j.athoracsur.2009.05.036.

[Treatment of malignant pleural mesothelioma].

Gan To Kagaku Ryoho. 2007 Apr;34(4):520-6.

[Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].

Zentralbl Chir. 2008 Jun;133(3):231-7. doi: 10.1055/s-2008-1076790.

[Malignant diffuse pleural mesothelioma therapy].

Dtsch Med Wochenschr. 1982 Jun 11;107(23):906-8. doi: 10.1055/s-2008-1070045.

Radiation therapy of mesothelioma: the Heidelberg experience and future aspects.

Lung Cancer. 2004 Aug;45 Suppl 1:S85-91. doi: 10.1016/j.lungcan.2004.04.026.

Malignant pleural mesothelioma: current treatments and emerging drugs.

Expert Opin Emerg Drugs. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563.

Thoracoscopic extrapleural pneumonectomy for mesothelioma.

Ann Thorac Surg. 2011 Feb;91(2):616-8. doi: 10.1016/j.athoracsur.2010.04.045.

引用本文的文献

Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.

J Cell Mol Med. 2012 Nov;16(11):2667-78. doi: 10.1111/j.1582-4934.2012.01584.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Current trends in the management of malignant pleural mesothelioma.

Expert Rev Anticancer Ther. 2006 Jun;6(6):831-3. doi: 10.1586/14737140.6.6.831.

[Therapy of malignant pleural mesothelioma].

Med Klin (Munich). 1991 May 15;86(5):259-62.

Integration of multimodality approaches in the management of malignant pleural mesothelioma.

Clin Lung Cancer. 2004 Mar;5(5):290-8. doi: 10.3816/CLC.2004.n.008.

Trimodality therapy for malignant pleural mesothelioma.

Ann Thorac Surg. 2009 Sep;88(3):870-5; discussion 876. doi: 10.1016/j.athoracsur.2009.05.036.

[Treatment of malignant pleural mesothelioma].

Gan To Kagaku Ryoho. 2007 Apr;34(4):520-6.

[Multimodal therapy for malignant pleural mesothelioma including extrapleural pneumonectomy].

Zentralbl Chir. 2008 Jun;133(3):231-7. doi: 10.1055/s-2008-1076790.

[Malignant diffuse pleural mesothelioma therapy].

Dtsch Med Wochenschr. 1982 Jun 11;107(23):906-8. doi: 10.1055/s-2008-1070045.

Radiation therapy of mesothelioma: the Heidelberg experience and future aspects.

Lung Cancer. 2004 Aug;45 Suppl 1:S85-91. doi: 10.1016/j.lungcan.2004.04.026.

Malignant pleural mesothelioma: current treatments and emerging drugs.

Expert Opin Emerg Drugs. 2009 Sep;14(3):423-37. doi: 10.1517/14728210903074563.

Thoracoscopic extrapleural pneumonectomy for mesothelioma.

Ann Thorac Surg. 2011 Feb;91(2):616-8. doi: 10.1016/j.athoracsur.2010.04.045.

引用本文的文献

Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.

J Cell Mol Med. 2012 Nov;16(11):2667-78. doi: 10.1111/j.1582-4934.2012.01584.x.